Yoel Z Betancor, Miriam Ferreiro-Pantín, Urbano Anido-Herranz, Mar Fuentes-Losada, Luis León-Mateos, Silvia Margarita García-Acuña, Vanessa Vaamonde-Rodríguez, Beatriz García-Pinel, Víctor Cebey-López, Rosa Villaverde-Viaño, Helena Lombardía-Rodríguez, Martin Kotrulev, Natalia Fernández-Díaz, Iria Gomez-Tourino, Carlos Fernández-Baltar, Jorge García-González, Jose M C Tubio, Rafael López-López, Juan Ruiz-Bañobre
In the advanced renal cell carcinoma (RCC) scenario, there are no consistent biomarkers to predict the clinical benefit patients derived from immune checkpoint blockade (ICB). Taking this into consideration, herein, we conducted a retrospective study in order to develop and validate a gene expression score for predicting clinical benefit to the anti-PD-1 antibody nivolumab in the context of patients diagnosed with advanced clear cell RCC enrolled in the CheckMate-009, CheckMate-010, and CheckMate-025 clinical trials...
2024: Frontiers in Immunology